Merit Medical Reports Q3 2026 Revenue Growth and Increased EPS Guidance
Merit Medical Systems (MMSI) delivered strong third-quarter results for fiscal year 2026, reporting revenue of $416.2 million, an 8.4% increase driven by robust demand in the U.S. market. Organic constant currency revenue growth reached 9%, surpassing management's high-end expectations. Non-GAAP EPS rose 22% year-over-year to $1.12, supported by strong performance across foundational and therapeutic product categories, including significant gains in endoscopy and oncology. Despite the top-line strength, the company faced pressure on gross margins due to manufacturing variances and higher freight costs. Management also adjusted its outlook for China, reducing second-half revenue expectations by approximately $4 million due to local procurement dynamics. However, the company remains on track with its long-term growth initiatives and has updated its full-year guidance upward for both revenue and earnings per share.
Tickers: $MMSI
Topics: Acquisition EPS Increase Free Cash Flow Operating Margin Revenue Growth